Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. 
IMBRUVICA (ibrutinib) is a prescription medicine used to treat people with marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment.

Type
Subsidiary
Parent Company
AbbVie
HQ
Sunnyvale, US
Founded
1991
Pharmacyclics was founded in 1991 and is headquartered in Sunnyvale, US
Report incorrect company information

Pharmacyclics Office Locations

Pharmacyclics has offices in Schaffhausen, Shanghai, South San Francisco and Sunnyvale
Sunnyvale, US (HQ)
999 E Arques Ave
South San Francisco, US
601 Gateway Blvd
Shanghai, CN
1551 Sichuan N Rd
Schaffhausen, CH
36 Mühlentalstrasse
Show all (4)
Report incorrect company information

Pharmacyclics Financials and Metrics

Summary Metrics

Founding Date

1991

Investors

Pharmacyclics is a subsidiary of AbbVie

Pharmacyclics Financials

Pharmacyclics's revenue was reported to be $729.73 m in FY, 2014 which is a 180.5% increase from the previous period.
Annual
USDFY, 2013FY, 2014

Revenue

260.2 m729.7 m

Revenue growth, %

180%

Cost of goods sold

Gross profit

260.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Revenue

79.1 m119.4 m113 m207.1 m205.8 m

Cost of goods sold

6.1 m9.3 m11.6 m16.7 m

Gross profit

113.3 m103.7 m195.5 m189.1 m

Gross profit Margin, %

95%92%94%92%
Annual
USDFY, 2013FY, 2014

Cash

624 m845 m

Accounts Receivable

11 m64.3 m

Inventories

9.3 m20.6 m

Current Assets

740.8 m1 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Cash

548.4 m678.6 m666.3 m724.5 m874.7 m

Accounts Receivable

53.8 m27 m45.3 m53.3 m77 m

Inventories

28.7 m38.3 m41.4 m49 m

Current Assets

624.4 m773 m783.5 m862.9 m1.1 b
Annual
USDFY, 2013FY, 2014

Net Income

117.5 m117.5 m

Depreciation and Amortization

595 k595 k

Accounts Payable

1.6 m1.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Net Income

42.3 m18.3 m(37.1 m)41.4 m4.1 m
Show all financial metrics
Report incorrect company information

Pharmacyclics News and Updates

A big drugmaker is backing away from a plan to triple the price of a lifesaving cancer drug after facing a public backlash

Drugmaker Pharmacyclics had tripled the cost of a lifesaving cancer blood treatment when it introduced a new version of the pill. The new price tag faced criticism from cancer doctors who were concerned about how this would impact how they dosed patients with the drug.  Last week, Pharmacyclics re…
Report incorrect company information